Acucela Inc. and Otsuka Pharmaceutical Co., Ltd. Announce Phase IIa Clinical Results of Emixustat Hydrochloride (ACU-4429) in Patients with Geographic Atrophy (GA) Associated with Dry Age-Related Macular Degeneration (AMD) at Association for Research in Vision & Ophthalmology 2013 Annual Meeting
5/9/2013 7:34:59 AM
More...
|
Acucela Inc. and Otsuka Pharmaceutical Co., Ltd. Announce the Initiation of a Phase 3 Clinical Trial to Evaluate Rebamipide Ophthalmic Suspension in Patients With Dry Eye Syndrome
7/19/2012 10:02:54 AM
More...
|
Acucela Inc. Appoints Business Leader and Entrepreneur Michael Schutzler to the Company’s Board of Directors
6/19/2012 10:14:15 AM
More...
|
Acucela Inc. Announces New Data from Its Phase 2a Trial of ACU-4429 in Patients With Advanced Dry AMD/Geographic Atrophy
5/8/2012 10:41:39 AM
More...
|
Acucela Inc. to Present Multiple Posters at The Association for Research in Vision & Ophthalmology 2012 Annual Meeting
4/24/2012 10:34:10 AM
More...
|
Acucela Inc. to Participate in Upcoming Retinal Physician Symposium in Miami, Florida
3/21/2012 6:15:40 AM
More...
|
Acucela Inc. to Present ACU-4429 Phase 1 Data at the 10th International Symposium on Ocular Pharmacology and Therapeutics
11/30/2011 9:11:30 AM
More...
|
Acucela Inc. and Otsuka Pharmaceutical Co., Ltd. Announce the Initiation of a Phase 1/2 Clinical Trial for OPA-6566 in Patients with Open-angle Glaucoma or Ocular Hypertension
9/13/2011 10:28:59 AM
More...
|
Acucela Inc. Appoints Michelle Carpenter, J.D., RAC, as Senior Vice President, Regulatory Affairs & Development Operations
8/8/2011 10:07:21 AM
More...
|
Acucela Inc. Appoints Former Bristol-Myers Squibb Company (BMY) and F. Hoffmann-La Roche Ltd. (RHHBY) Executive, Jaisim Shah, to the Company’s Board of Directors
8/3/2011 8:06:19 AM
More...
|
|